


**IN THE CLAIMS:**

Please amend the claims as follows:

Claim 1 (original): A compound for inhibiting the activity of PARP having formula I


:



and pharmaceutically acceptable salts thereof.


Claim 2 (original): A compound for inhibiting the activity of PARP having formula II

:



and pharmaceutically acceptable salts thereof.


Claim 3 (original): A compound for inhibiting the activity of PARP having formula




and pharmaceutically acceptable salts thereof.

Claim 4 (original): A compound according to claim 1, wherein the compound is in the form of a phosphate salt of the following formula: Formula I-phosphate


**Formula I - phosphate**




Claim 5 (currently amended): The use of a therapeutic amount of a compound of formula I according to claim 1, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament.



Claim 6 (currently amended): The use of a therapeutic amount of a compound of formula II according to claim 2, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament.



Claim 7 (currently amended): The use of a therapeutic amount of a compound of formula III according to claim 3, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament.



Claim 8 (currently amended): The use of a therapeutic amount of a compound of formula I according to claim 1, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment of a disease or condition that is caused by a genetic defect in a gene that mediates homologous recombination.

Claim 9 (currently amended): The use of a therapeutic amount of a compound of formula II according to claim 2, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment of a disease or condition that is caused by a genetic defect in a gene that mediates homologous recombination.

Claim 10 (currently amended): The use of a therapeutic amount of a compound of formula III according to claim 3, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment of a disease or condition that is caused by a genetic defect in a gene that mediates homologous recombination.

Claim 11 (currently amended): The use as claimed in ~~any one of claims 8 to 10~~ claim 8, wherein the defect is a gene encoding a protein involved in HR.

Claim 12 (currently amended): The use as claimed in ~~any one of claims 8 to 10~~ claim 8, wherein the defect is the absence of a gene encoding a protein involved in HR.

Claim 13 (currently amended): The use as claimed in ~~any one of claims 8 to 10~~ claim 8, wherein the defect is in the expression of a gene encoding a protein involved in

HR.

Claim 14 (currently amended): The use of a therapeutically effective amount of a compound of formula I according to claim 1 and pharmaceutically acceptable salts thereof, in the manufacture of a medicament for inducing apoptosis in HR defective cells.

Claim 15 (currently amended): The use of a therapeutically effective amount of a compound of formula II according to claim 2, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament for inducing apoptosis in the defective cells.

Claim 16 (currently amended): The use of a therapeutically effective amount of a compound of formula III according to claim 3, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament for inducing apoptosis in the defective cells.

Claim 17 (currently amended): The use of a therapeutically effective amount of a compound of formula I according to claim 1, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment of cancer.

Claim 18 (currently amended): The use of a therapeutically effective amount of a compound of formula II according to claim 2, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment of cancer.

Claim 19 (currently amended): The use of a therapeutically effective amount of a

compound of formula III according to claim 3, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment of cancer.

Claim 20 (currently amended): The use of a compound according to ~~any one of claims 15 to 17~~ claim 15, wherein the cancer is gene-linked hereditary cancer.

Claim 21 (currently amended): The use of a therapeutically effective amount of a compound of formula I according to claim 1, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment of cancer cells defective in BRCA1 and/or BRCA2 expression.

Claim 22 (currently amended): The use of a therapeutically effective amount of a compound of formula II according to claim 2, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment of cancer cells defective in BRCA1 and/or BRCA2 expression.

Claim 23 (currently amended): The use of a therapeutically effective amount of a compound of formula III according to claim 3, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment of cancer cells defective in BRCA1 and/or BRCA2 expression.

Claim 24 (currently amended): The use of a compound ~~according to any one of claims 21 to 23~~ claim 21, wherein the cancer cells to be treated are partially or totally

deficient in BRCA1 and/or BRCA2 expression.

Claim 25 (currently amended): A pharmaceutical composition comprising a compound of formula I according to claim 1, and a pharmaceutically acceptable salt thereof, as an active ingredient.

Claim 26 (currently amended): A pharmaceutical composition comprising a compound of formula II according to claim 2, a pharmaceutically acceptable salt thereof, as an active ingredient.

Claim 27 (currently amended): A pharmaceutical composition comprising a compound of formula III according to claim 3 and a pharmaceutically acceptable salt thereof, as an active ingredient.

Claim 28 (currently amended): A pharmaceutical composition according to ~~any one of claims 25 to 27~~ according to claim 25, wherein the composition further comprises at least one diluent and/or carrier together with at least one bulking agent.

Claim 29 (original): A pharmaceutical composition according to claim 28, wherein the carrier and/or diluent is selected from any of the following either alone or in combination, saline, buffered saline, dextrose, water, glycerol and ethanol.

Claim 30 (currently amended): A method for the treatment of cancer in mammals

comprising administering a compound of formula I as described in claim 1, or a pharmaceutically acceptable salt thereof[[:]].

Claim 31 (currently amended): A method for the treatment of cancer in mammals comprising administering a compound of formula II as described in claim 2, or a pharmaceutically acceptable salt thereof[[:]].

Claim 32 (currently amended): A method for the treatment of cancer in mammals comprising administering a compound of formula III as described in claim 3, or a pharmaceutically acceptable salt thereof[[:]].